WO2023067522 - PHARMACEUTICAL COMPOSITIONS
National phase entry:
Publication Number
WO/2023/067522
Publication Date
27.04.2023
International Application No.
PCT/IB2022/060061
International Filing Date
19.10.2022
Title **
[English]
PHARMACEUTICAL COMPOSITIONS
[French]
COMPOSITIONS PHARMACEUTIQUES
Applicants **
NOVARTIS AG
Inventors
BHASIN, Saket
KULKARNI, Swati
Priority Data
202111047878
21.10.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2668 | |
| EPO | Filing, Examination, Granting | 18093 | |
| Japan | Filing, Examination, Granting | 2740 | |
| South Korea | Filing, Examination, Granting | 3257 | |
| USA | Filing, Examination, Granting | 9340 |

Total:
36,098
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
-spiro[imidazo[1,2- ]pyridine-2,5'-isoquinoline], or a pharmaceutically acceptable salt thereof, or a free form thereof are described. Further, processes for preparing said pharmaceutical 5 compositions for oral administration and uses of said pharmaceutical compositions in the manufacture of a medicament are described.[French]
-spiro [imidazo [1,2-]pyridine-2,5'-isoquinoline], ou un sel pharmaceutiquement acceptable de celui-ci, ou une forme libre de celui-ci. En outre, l'invention concerne des procédés de préparation desdites compositions pharmaceutiques pour une administration orale et des utilisations desdites compositions pharmaceutiques dans la fabrication d'un médicament.